Cecilie Dyg Sperling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cecilie Dyg Sperling has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Bibi Hølge-Hazelton
Department of Regional Health Research University of Southern Denmark Odense Denmark
2 shared publications - Christian Graugaard
Center for Sexology Research, Department of Clinical Medicine Aalborg University Aalborg Denmark
2 shared publications Freija Verdoodt
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
2 shared publicationsJanne Lehmann Knudsen
Documentation & Quality, the Danish Cancer Society , Copenhagen, Denmark
2 shared publications- Kirsten Arntz Boisen
Center of Adolescent Medicine, Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
2 shared publications - Susanne Kriiger Kjaer
Unit of Virus, Lifestyle and Genes Danish Cancer Institute Copenhagen Denmark
2 shared publications
Latest Publications
- 1 May 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 161 (2) , 553-558
A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer
- 1 May 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 161 (2) , 553-558
A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer
- 23 February 2021
- Published by Springer Nature in Cancer Causes & Control
- Vol. 32 (5) , 515-523
Non-aspirin NSAID use and mortality of endometrial cancer. A nationwide cohort study
Purpose Laboratory studies have shown anti-neoplastic properties of non-aspirin NSAID; however, no studies have examined the influence of non-aspirin NSAIDs as potential adjuvant cancer therapy in women with endometrial cancer. We therefore examined the association between post-diagnostic use of non-aspirin NSAIDs and endometrial cancer mortality in Denmark. Methods We identified all women with a primary endometrial cancer diagnosis between 2000 and 2012, who were alive one year after the diagnosis. Information on drug use, cause-specific mortality and potential confounders was obtained from nationwide health- and demographic registries. Cox regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between post-diagnostic non-aspirin NSAID use and endometrial cancer mortality. Results Among 6 694 endometrial cancer patients with a maximum follow-up of 13 years, 753 women died from endometrial cancer. Post-diagnostic non-aspirin NSAID use (≥ 1 filled prescription) was associated with an overall HR of 1.15 (95% CI; 0.97–1.36) for endometrial cancer mortality, with higher HRs for the highest intensity of use (HR; 1.40, 95% CI; 1.11–1.77) and largest cumulative amount (HR; 1.56, 95% CI; 1.14–2.14). Conclusion Our findings yielded no evidence that use of non-aspirin NSAIDs was associated with reduced endometrial cancer. Rather, we observed that high-intensity and large cumulative amount of non-aspirin NSAID use may be associated with increased endometrial cancer mortality.
- 23 February 2021
- Published by Springer Nature in Cancer Causes & Control
- Vol. 32 (5) , 515-523
Non-aspirin NSAID use and mortality of endometrial cancer. A nationwide cohort study
Purpose Laboratory studies have shown anti-neoplastic properties of non-aspirin NSAID; however, no studies have examined the influence of non-aspirin NSAIDs as potential adjuvant cancer therapy in women with endometrial cancer. We therefore examined the association between post-diagnostic use of non-aspirin NSAIDs and endometrial cancer mortality in Denmark. Methods We identified all women with a primary endometrial cancer diagnosis between 2000 and 2012, who were alive one year after the diagnosis. Information on drug use, cause-specific mortality and potential confounders was obtained from nationwide health- and demographic registries. Cox regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between post-diagnostic non-aspirin NSAID use and endometrial cancer mortality. Results Among 6 694 endometrial cancer patients with a maximum follow-up of 13 years, 753 women died from endometrial cancer. Post-diagnostic non-aspirin NSAID use (≥ 1 filled prescription) was associated with an overall HR of 1.15 (95% CI; 0.97–1.36) for endometrial cancer mortality, with higher HRs for the highest intensity of use (HR; 1.40, 95% CI; 1.11–1.77) and largest cumulative amount (HR; 1.56, 95% CI; 1.14–2.14). Conclusion Our findings yielded no evidence that use of non-aspirin NSAIDs was associated with reduced endometrial cancer. Rather, we observed that high-intensity and large cumulative amount of non-aspirin NSAID use may be associated with increased endometrial cancer mortality.
- 23 June 2020
- Published by Wiley in Head & Neck
- Vol. 42 (10) , 2975-2984
Prevalence of human papillomavirus in oral epithelial dysplasia: Systematic review and meta‐analysis
The purpose of this systematic review and meta‐analysis was to estimate the overall and type‐specific prevalence of human papillomavirus (HPV) DNA in oral epithelial dysplasia and assess p16INK4a overexpression in relation to HPV‐status. A systematic literature search identified 31 eligible studies (832 cases) evaluating the presence of HPV DNA in oral epithelial dysplasia cases by PCR. Of these, six studies evaluated p16INK4a overexpression in relation to HPV‐status. The overall pooled prevalence of HPV DNA in oral epithelial dysplasia was 27.2% (95% CI: 17.6‐38.1). We observed substantial interstudy heterogeneity, which could not be explained by differences in continent, tissue type, or severity of epithelial dysplasia. HPV16 was the predominant genotype detected. Moreover, 62.2% of HPV positive and 17.8% of HPV negative oral epithelial dysplasia samples stained intensively positive for p16INK4a. This meta‐analysis found that 27% of oral epithelial dysplasia harbor HPV DNA. Whether this represents a transient infection or has a carcinogenic role is unknown.
- 23 June 2020
- Published by Wiley in Head & Neck
- Vol. 42 (10) , 2975-2984
Prevalence of human papillomavirus in oral epithelial dysplasia: Systematic review and meta‐analysis
The purpose of this systematic review and meta‐analysis was to estimate the overall and type‐specific prevalence of human papillomavirus (HPV) DNA in oral epithelial dysplasia and assess p16INK4a overexpression in relation to HPV‐status. A systematic literature search identified 31 eligible studies (832 cases) evaluating the presence of HPV DNA in oral epithelial dysplasia cases by PCR. Of these, six studies evaluated p16INK4a overexpression in relation to HPV‐status. The overall pooled prevalence of HPV DNA in oral epithelial dysplasia was 27.2% (95% CI: 17.6‐38.1). We observed substantial interstudy heterogeneity, which could not be explained by differences in continent, tissue type, or severity of epithelial dysplasia. HPV16 was the predominant genotype detected. Moreover, 62.2% of HPV positive and 17.8% of HPV negative oral epithelial dysplasia samples stained intensively positive for p16INK4a. This meta‐analysis found that 27% of oral epithelial dysplasia harbor HPV DNA. Whether this represents a transient infection or has a carcinogenic role is unknown.
- 17 December 2019
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 49 (1) , 330-337
Low-dose aspirin use and endometrial cancer mortality—a Danish nationwide cohort study
Background: Accumulating evidence suggests that aspirin use may improve survival in cancer patients, however, for endometrial cancer, epidemiological evidence is limited and results are equivocal. In a nationwide cohort study, we examined the association between post-diagnostic low-dose aspirin use and endometrial cancer mortality. Methods: From the Danish Cancer Registry, we identified all women with a primary diagnosis of endometrial cancer. Women diagnosed between 2000 and 2012, aged 30–84 years, who had no history of cancer (except non-melanoma skin cancer) and were alive 1 year after the cancer diagnosis were eligible. We obtained information on pre- and post-diagnostic use (≥1 prescription) of low-dose aspirin, mortality and potential confounding factors from nationwide registries. Using Cox regression models, we estimated adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between post-diagnostic low-dose aspirin use and endometrial cancer mortality. The exposure was modelled as both time-varying as well as time-fixed within exposure windows of 1 and 5 years. Results: We identified 6694 endometrial cancer patients with a maximum follow-up of 13 years. In the time-varying analysis, post-diagnostic low-dose aspirin use was associated with a HR of 1.10 (95% CI 0.90–1.33) for endometrial cancer mortality. We found no indication of a dose–response association according to increasing tablet strength, cumulative amount or duration of use, and the HRs were similar for pre-diagnostic and post-diagnostic low-dose aspirin use compared with non-use. Conclusions: We found no indication that post-diagnostic low-dose aspirin use was associated with reduced mortality for endometrial cancer; rather our findings suggested a concern for increased mortality.
- 17 December 2019
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 49 (1) , 330-337
Low-dose aspirin use and endometrial cancer mortality—a Danish nationwide cohort study
Background: Accumulating evidence suggests that aspirin use may improve survival in cancer patients, however, for endometrial cancer, epidemiological evidence is limited and results are equivocal. In a nationwide cohort study, we examined the association between post-diagnostic low-dose aspirin use and endometrial cancer mortality. Methods: From the Danish Cancer Registry, we identified all women with a primary diagnosis of endometrial cancer. Women diagnosed between 2000 and 2012, aged 30–84 years, who had no history of cancer (except non-melanoma skin cancer) and were alive 1 year after the cancer diagnosis were eligible. We obtained information on pre- and post-diagnostic use (≥1 prescription) of low-dose aspirin, mortality and potential confounding factors from nationwide registries. Using Cox regression models, we estimated adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between post-diagnostic low-dose aspirin use and endometrial cancer mortality. The exposure was modelled as both time-varying as well as time-fixed within exposure windows of 1 and 5 years. Results: We identified 6694 endometrial cancer patients with a maximum follow-up of 13 years. In the time-varying analysis, post-diagnostic low-dose aspirin use was associated with a HR of 1.10 (95% CI 0.90–1.33) for endometrial cancer mortality. We found no indication of a dose–response association according to increasing tablet strength, cumulative amount or duration of use, and the HRs were similar for pre-diagnostic and post-diagnostic low-dose aspirin use compared with non-use. Conclusions: We found no indication that post-diagnostic low-dose aspirin use was associated with reduced mortality for endometrial cancer; rather our findings suggested a concern for increased mortality.
- 21 September 2016
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 6 (1) , 171-177
Being Young and Getting Cancer: Development of a Questionnaire Reflecting the Needs and Experiences of Adolescents and Young Adults with Cancer
Purpose: Cancer is the leading cause of nonaccidental deaths among adolescents and young adults (AYAs). In Denmark, there are substantial gaps in knowledge concerning how AYAs with cancer perceive their diagnostic and therapeutic trajectory and report health-related outcomes. The aim of this study is to describe the development of a questionnaire targeting AYAs with cancer aiming to evaluate treatment and survivorship from the perspective of the patients. Methods: Identification of themes and development of items included in the questionnaire were based on a synthesis of literature and qualitative interviews with AYAs in an iterative process involving both a professional advisory panel and a youth panel. During the development process, items were validated through cognitive interviews. Results: The final questionnaire contained 151 closed- and open-ended items divided into 6 sections regarding: (1) “Time before treatment,” (2) “Being told about your illness,” (3) “Being a young patient,” (4) “Your treatment,” (5) “Receiving help living with and after Cancer,” and (6) “How are you feeling today?.” One hundred one items were specifically developed for this study, while 50 were standardized validated indexes. The questionnaire combined different types of items such as needs, preferences, experiences, and patient-reported outcomes. Conclusion: This is one of few developed questionnaires aiming to evaluate the perspective of AYAs with cancer through their whole cancer trajectory. Results from the questionnaire survey are intended for quality improvements and research in AYA cancer care. The study highlights the importance of an extensive patient involvement in all steps of a questionnaire development process.
- 21 September 2016
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 6 (1) , 171-177
Being Young and Getting Cancer: Development of a Questionnaire Reflecting the Needs and Experiences of Adolescents and Young Adults with Cancer
Purpose: Cancer is the leading cause of nonaccidental deaths among adolescents and young adults (AYAs). In Denmark, there are substantial gaps in knowledge concerning how AYAs with cancer perceive their diagnostic and therapeutic trajectory and report health-related outcomes. The aim of this study is to describe the development of a questionnaire targeting AYAs with cancer aiming to evaluate treatment and survivorship from the perspective of the patients. Methods: Identification of themes and development of items included in the questionnaire were based on a synthesis of literature and qualitative interviews with AYAs in an iterative process involving both a professional advisory panel and a youth panel. During the development process, items were validated through cognitive interviews. Results: The final questionnaire contained 151 closed- and open-ended items divided into 6 sections regarding: (1) “Time before treatment,” (2) “Being told about your illness,” (3) “Being a young patient,” (4) “Your treatment,” (5) “Receiving help living with and after Cancer,” and (6) “How are you feeling today?.” One hundred one items were specifically developed for this study, while 50 were standardized validated indexes. The questionnaire combined different types of items such as needs, preferences, experiences, and patient-reported outcomes. Conclusion: This is one of few developed questionnaires aiming to evaluate the perspective of AYAs with cancer through their whole cancer trajectory. Results from the questionnaire survey are intended for quality improvements and research in AYA cancer care. The study highlights the importance of an extensive patient involvement in all steps of a questionnaire development process.
- 28 June 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (11) , 4727-4737
“Perhaps I will die young.” Fears and worries regarding disease and death among Danish adolescents and young adults with cancer. A mixed method study
Purpose A cross-sectional national study was initiated in order to evaluate healthcare services and survivorship from the perspective of Danish adolescents and young adults (AYAs) with cancer. The purpose of the paper was to examine (Q1) to what extend Danish AYAs experienced fears and worries about dying; (Q2) with whom, if anyone, they had shared those worries; and finally, (Q3) how fears and worries influenced their daily life. The emphasis will be on Q3. Methods A 151-item questionnaire (including two closed- and one open-ended questions about fears of death and dying) was distributed among all 15–29-year-old Danes registered with a cancer diagnosis from 2009 to 2013. A total study population of 822 persons participated. Data was analyzed using a mixed design of descriptive statistics and qualitative content analysis. Results Q1: Almost 80 % of AYAs with cancer expressed some worries about death; hereof, more than half of them expressed quite a bit or very much. The analysis showed significant gender differences, whereas age and duration of disease did not have any significant impact on such thoughts. Q2: One third had not talked to anybody about his or her worries. Q3: The analysis resulted in three overall categories: fear of disease and death having little or no influence (n = 100), fear influencing in various ways (n = 215), and fear of disease and death having a substantial influence (n = 75). Conclusions The majority of AYAs had experienced fears and worries about dying, but one third of them had not talked to anybody about those thoughts. It is an important clinical point that young age does not preclude fears and worries about dying in AYAs with cancer.
- 28 June 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (11) , 4727-4737
“Perhaps I will die young.” Fears and worries regarding disease and death among Danish adolescents and young adults with cancer. A mixed method study
Purpose A cross-sectional national study was initiated in order to evaluate healthcare services and survivorship from the perspective of Danish adolescents and young adults (AYAs) with cancer. The purpose of the paper was to examine (Q1) to what extend Danish AYAs experienced fears and worries about dying; (Q2) with whom, if anyone, they had shared those worries; and finally, (Q3) how fears and worries influenced their daily life. The emphasis will be on Q3. Methods A 151-item questionnaire (including two closed- and one open-ended questions about fears of death and dying) was distributed among all 15–29-year-old Danes registered with a cancer diagnosis from 2009 to 2013. A total study population of 822 persons participated. Data was analyzed using a mixed design of descriptive statistics and qualitative content analysis. Results Q1: Almost 80 % of AYAs with cancer expressed some worries about death; hereof, more than half of them expressed quite a bit or very much. The analysis showed significant gender differences, whereas age and duration of disease did not have any significant impact on such thoughts. Q2: One third had not talked to anybody about his or her worries. Q3: The analysis resulted in three overall categories: fear of disease and death having little or no influence (n = 100), fear influencing in various ways (n = 215), and fear of disease and death having a substantial influence (n = 75). Conclusions The majority of AYAs had experienced fears and worries about dying, but one third of them had not talked to anybody about those thoughts. It is an important clinical point that young age does not preclude fears and worries about dying in AYAs with cancer.
- 1 June 2014
- Vol. 61 (6) , A4855
Current organisation of follow-up does not meet cancer patients' needs.
For cancer patients, traditional follow-up care is considered unsuitable and unsustainable. The patient perspective seems often to be absent in the ongoing debate about alternative strategies for follow-up care. Based on a national survey from 2012, the objective of this study was to examine cancer patients' support needs regarding physiological and emotional problems during follow-up and to identify factors associated with their needs and any unmet needs. Patients diagnosed with cancer in the period from April to September 2010 were invited to participate. A total of 4,401 patients responded (response rate = 64%). The risks in terms of prevalence rate ratios of having needs and unmet needs for both physiological and emotional problems were estimated using the Poisson regression. The study showed that 60% of the patients had needs for support regarding physiological and emotional problems, and half of the patients reported unmet needs. Younger patients and patients with co-morbidity were more likely to report needs and unmet needs for physiological and emotional support. Treatment complexity and setting of follow-up were not associated with unmet needs. The study underlines that the current organisation of follow-up does not meet cancer patients' needs. Several factors are associated with both needs and unmet needs. Hence, a more sustainable approach for follow-up care may consist in stratification tailored to the patients' different needs. In such an approach, more focus should be on age-specific needs and the impact of co-morbidity. The study is funded by the Danish Cancer Society. The study was approved by the Danish Data Protection Agency (J. no. 2010-41-4694). According to the Danish Act on Research Ethics Review of Health Research Projects (S. 8(3) of Act No. 402 of 28 May 2003), no ethical approval was needed.
- 1 June 2014
- Vol. 61 (6) , A4855
Current organisation of follow-up does not meet cancer patients' needs.
For cancer patients, traditional follow-up care is considered unsuitable and unsustainable. The patient perspective seems often to be absent in the ongoing debate about alternative strategies for follow-up care. Based on a national survey from 2012, the objective of this study was to examine cancer patients' support needs regarding physiological and emotional problems during follow-up and to identify factors associated with their needs and any unmet needs. Patients diagnosed with cancer in the period from April to September 2010 were invited to participate. A total of 4,401 patients responded (response rate = 64%). The risks in terms of prevalence rate ratios of having needs and unmet needs for both physiological and emotional problems were estimated using the Poisson regression. The study showed that 60% of the patients had needs for support regarding physiological and emotional problems, and half of the patients reported unmet needs. Younger patients and patients with co-morbidity were more likely to report needs and unmet needs for physiological and emotional support. Treatment complexity and setting of follow-up were not associated with unmet needs. The study underlines that the current organisation of follow-up does not meet cancer patients' needs. Several factors are associated with both needs and unmet needs. Hence, a more sustainable approach for follow-up care may consist in stratification tailored to the patients' different needs. In such an approach, more focus should be on age-specific needs and the impact of co-morbidity. The study is funded by the Danish Cancer Society. The study was approved by the Danish Data Protection Agency (J. no. 2010-41-4694). According to the Danish Act on Research Ethics Review of Health Research Projects (S. 8(3) of Act No. 402 of 28 May 2003), no ethical approval was needed.
- 1 April 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 129 (1) , 97-102
Comorbidity is an independent prognostic factor for the survival of ovarian cancer: A Danish register-based cohort study from a clinical database
- 1 April 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 129 (1) , 97-102
Comorbidity is an independent prognostic factor for the survival of ovarian cancer: A Danish register-based cohort study from a clinical database